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Abstract
Objective: To document trends in invasive pneumococcal disease (IPD) in a central hospital in Malawi during the period of
national scale-up of antiretroviral therapy (ART) and cotrimoxazole prophylaxis.
Methods: Between 1 January 2000 and 31 December 2009 almost 100,000 blood cultures and 40,000 cerebrospinal fluid
(CSF) cultures were obtained from adults and children admitted to the Queen Elizabeth Central Hospital, Blantyre, Malawi
with suspected severe bacterial infection.
Results: 4,445 pneumococcal isolates were obtained over the 10 year period. 1,837 were from children: 885 (19.9%) from
blood and 952 (21.4%) from CSF. 2,608 were from adults: 1,813 (40.8%) from blood and 795 (17.9%) from CSF. At the start of
the surveillance period cotrimoxazole resistance was 73.8% and at the end was 92.6%. Multidrug resistance (MDR) was
present in almost one third of isolates and was constant over time. Free ART was introduced in Malawi in 2004. From 2005
onwards there was a decline in invasive pneumococcal infections with a negative correlation between ART scale-up and the
decline in IPD (Pearson’s correlation r =20.91; p,0.001).
Conclusion: During 2004–2009, national ART scale-up in Malawi was associated with a downward trend in IPD at QECH. The
introduction of cotrimoxazole prophylaxis in HIV-infected groups has not coincided with a further increase in pneumococcal
cotrimoxazole or multidrug resistance. These data highlight the importance of surveillance for high disease burden
infections such as IPD in the region, which will be vital for monitoring pneumococcal conjugate vaccine introduction into
national immunisation programmes.
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Introduction
Approximately 1.1 million deaths annually are attributed to
invasive pneumococcal disease (IPD) worldwide, accounting for
9% of all deaths in developing countries [1,2,3,4]. Pneumococcal
meningitis and bloodstream infections are frequently HIV-related,
especially in adults, and are associated with a high mortality
[5,6,7,8,9].
In Malawi, S. pneumoniae is a leading cause of pneumonia, sepsis,
bacterial meningitis and death in both children and adults
[6,8,10]. Malawi is a landlocked country in southern Africa that
lies to the south of the classical meningitis belt [11] and to the
north of South Africa, a key economic partner in terms of trade
and workforce movement. It has a high HIV prevalence and in
2007, the estimate of those living with HIV infection in Malawi
was approximately 900,000 [12]. In Blantyre, the prevalence of
HIV infection in paediatric inpatients is approximately 19%
overall [13], and 34% in children with bacterial meningitis [14].
Adult inpatient HIV prevalence is approximately 70% [15],
reaching up to 90% in meningitis cases [6,16,17].
Free antiretroviral therapy (ART) has been provided in Malawi
since 2004 through the support of the Global Fund [18]. By the
end of 2009, 271,105 HIV-infected individuals had been
registered on the national ART programme of which, 198,846
patients were alive and on ART at 377 ART clinics in Malawi
[19]. Alongside the rapid ART scale-up, cotrimoxazole prophy-
laxis has been widely implemented. Although registration of
cotrimoxazole prophylaxis did not begin until 2006, by 2010 there
were over 250,000 patients registered [20].
It has been reported in the United States and South Africa that
ART introduction has led to a reduction in the burden of IPD
[21,22]. Antibiotic resistance complicates the clinical management
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of invasive pneumococcal disease (IPD), particularly in resource-
poor settings such as sub-Saharan Africa (SSA) where resistance to
a range of commonly used antibiotics has been reported
[23,24,25,26,27,28,29] and the dissemination of pandemic
multidrug resistant (MDR) clones is a major global health concern
[25,27,30]. Cotrimoxazole prophylactic treatment of HIV-infected
individuals has the potential to amplify bacterial resistance
[31,32,33]. We therefore analysed 10 years of surveillance data
at the Queen Elizabeth Central Hospital (QECH), the only
government-funded hospital serving the largest city in Malawi,
Blantyre. We sought to investigate whether there has been a
change in the frequency and seasonal pattern of IPD as the
national ART program has scaled-up; and to determine whether
cotrimoxazole prophylaxis has led to an increase in resistance to
this and other frequently used antibiotics.
Methods
Setting
QECH is a 1250-bed government funded central hospital that
provides primary to tertiary care and has an average admission
rate of 50,000 patients per year (see below). QECH serves a
population of approximately 1 million including the city of
Blantyre, the surrounding townships, and outlying villages.
Patients and surveillance criteria for invasive bacterial
infection
During the period studied, all adult general medical admissions
(15-years or older) presenting with fever (axillary temperature
.37.5uC) or clinical evidence of sepsis had a recommended 5-10-
mL of blood drawn for culture. Lumbar punctures (LP) were
performed when there was a clinical suspicion of meningitis.
Malaria is a common cause of febrile illness among children in
Malawi, and all children first had a thick blood film obtained from
a capillary sample examined for malaria parasites. Blood culture
(1-mL) or LP were reserved for febrile children who had a negative
thick film for malaria parasites and no obvious clinical focus of
infection (such as pneumonia), children considered severely ill with
sepsis or meningitis regardless of thick film result, and patients who
failed to respond to initial treatment for malaria and remained
febrile. During 2000, aerobic blood culture was performed using a
manual culture system.
S. pneumoniae isolation and identification
Blood was inoculated into a single 50-mL (adult) or 20-mL
(paediatric) bottle of brain heart infusion broth with sodium
polyanethol sulphonate (E&O laboratories, UK) and was incubat-
ed at 37uC in air for 7 days, with routine subcultures onto sheep
blood agar in 5% CO2 at 24-h, 48-h, and 7 days. Turbid bottles
were examined by Gram stain and subcultured onto appropriate
media. From December 2000 onwards the same volume of blood
was cultured using the BacT/Alert 3D automated system
(BioMerieux, UK). All isolates were identified using standard
diagnostic techniques [34]. Cerebrospinal fluid (CSF, 5-10-mL
from adults and 1-2-mL from children) was analysed by Gram
stains if the white blood cell (WBC) count was .10/mm3. All
samples were cultured on sheep blood agar for 48-h under aerobic
and microaerophilic (candle jar) conditions. Organisms were
identified using standard methods including alpha-haemolysis and
optochin sensitivity [34].
All diagnostic testing and quality control was performed in the
laboratories of the Malawi-Liverpool-Wellcome Trust Clinical
Research Programme (MLW) as part of a routine service provided
to support QECH. The MLW laboratory participates in a number
of internationally recognised quality control programmes. During
2004–2006, two large clinically based studies situated in QECH
provided enhanced S. pneumoniae surveillance in adults and focused
heavily on improved sample collection practices, particularly
blood culture collection [8,35].
Susceptibility Testing
Antibiotic susceptibilities to ceftriaxone, chloramphenicol,
cotrimoxazole, erythromycin, oxacillin, and tetracycline were
determined on all isolates by disc testing (Oxoid, UK) using the
British Society for Antimicrobial Chemotherapy (BSAC) sensitivity
method for direct cultures [36]. At QECH isolates are reported as
sensitive, resistant or of intermediate susceptibility to each
antibiotic tested based on zone size measurement.
National HIV intervention strategies
Data on ART scale-up and the cotrimoxazole prophylaxis
register was obtained from the Malawi Ministry of Health [20,37].
Rainfall and Temperature
Although there a few detailed reports, IPD is widely believed to
be seasonal in SSA. To establish whether this seasonality has been
retained over the surveillance period, rainfall and temperature
data were obtained from the Department of Climate Change and
Meteorological Services, Malawi for the two nearest meteorolog-
ical stations to Blantyre (Chileka and Chichiri). Mean rainfall and
mean temperature per month for the two areas were used to
obtain estimates for Blantyre.
Ethical Approval
The isolates characterised in this study are all clinical isolates
from CSF and blood culture specimens obtained from Malawian
adults and children as part of routine clinical diagnosis and
management when they were admitted to QECH. The main
ethical issue relates to specific consent for detailed characterisation
of an isolate from a clinical specimen taken from a patient on
clinical grounds. This requirement was waived by the University of
Malawi, College of Medicine Research & Ethics Committee
because the characterisation formed part of routine clinical
management. The data are therefore published with the approval
of the Research & Ethics Committee and conform to institutional
guidelines.
Results
The MLW laboratory processed 99,741 (50,110 adult; 49,631
paediatric) blood cultures and 39,694 (19,213 adult; 20,481
paediatric) CSF cultures from adults and children admitted to
QECH, Blantyre, Malawi with suspected severe bacterial infection
between 1st January 2000 and 31st December 2009. During the
same period, a total of 4445 pneumococcal isolates were obtained.
1837 were from children: 885 (19.9%) from blood and 952
(21.4%) from CSF. 2608 were from adults: 1813 (40.8%) from
blood and 795 (17.9%) from CSF. In 80 illness episodes,
pneumococci were isolated from both a blood and a CSF sample
from the same individual.
The median (IQR) ages were 0.8 (0.2–3.4) and 31 (26–39) years
respectively for paediatric and adult patients with pneumococcal
isolates. Hospital admission data was only available from 2002
onwards. During this period, admissions remained at consistent
level of around 50,000 per year. The lowest yearly admission rate
was 45,896 in 2009 and the maximum was 58,414 in 2003. In the
same period the number of blood cultures collected from those
Pneumococcal Surveillance in Malawi
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admitted averaged 10,000 per year. The minimum collection was
8033 in 2009 and the maximum was 12,430 in 2003.
There was a decline year on year of microbiologically confirmed
IPD from a peak of 744 cases in 2005, during a period of
enhanced surveillance, to 171 cases in 2009 which coincided with
a year on year scale up of ART provision (Figure 1). There was a
negative correlation between ART scale-up and the decline in
microbiologically confirmed invasive pneumococcal disease (Pear-
son’s correlation r =20.91; p,0.001) over this time period.
The blood culture recovery rate per blood culture taken year on
year peaked in paediatric and adult samples at 2.31% in 2004 and
6.74% in 2005 respectively. By 2009 the rate had dropped to
0.85% and 2.46% respectively. The CSF recovery rate per CSF
sample peaked in paediatric and adult samples at 7.62% in 2004
and 5.78% in 2001 respectively. By 2009 the rate had dropped to
2.85% and 3.01% respectively (Figure 2).
There was a decrease in the number of confirmed adult and
paediatric pneumococcal infections from 2005 through 2009
(Figure 3). The decline in adults was the most marked from 488
cases in 2005 to 96 cases in 2009. A decrease year-on-year was also
observed in the number of non-typhoidal salmonellae (NTS)
isolates from adult blood cultures. NTS decreased from 758 cases
in 2003 to 180 cases in 2009 (Figure 4).
Seasonality
Mean temperatures in Blantyre over the decade ranged from
17–25uC, but the pattern of seasonal variation remained stable
according to season, peaking in October/November with the
coldest and driest months being June/July (Figure 5). The peak
rainfall was observed in the months of January-March. The
incidence of pneumococcal isolation peaked during the colder,
drier months. Since 2005 this relationship has become more
pronounced. Seasonality was present both in adults who had a
higher HIV seroprevalence, and children, who had a relatively
lower HIV seroprevalence (data not shown).
Antibiotic resistance patterns
Resistance to the six first line antibiotics at QECH by year was
recorded routinely throughout the study period (Figure 6). There
was no reported resistance to ceftriaxone since its introduction.
Chloramphenicol resistance has remained within the range of 20–
33%. Cotrimoxazole resistance was already high at around 74%
when data collection began, and it increased by almost 20%
during 2002, since when it has remained consistently above 90%.
The increase in cotrimoxazole resistance levels was not associated
with increased resistance to other drugs (Table 1). Erythromycin
resistance was consistently below 2%. Penicillin resistance
remained within the range of 9–18% over the decade, and has
been stable at approximately 10% since 2005. Tetracycline
resistance varied between 50–63% throughout the decade. In
Malawi, the combination of penicillin and chloramphenicol is a
commonly used empirical regimen for suspected IPD in adults.
Since 2000 the rate of combined resistance to both drugs remained
between 1–2% of all microbiologically confirmed pneumococcal
infections (data not shown), resistance to either of the drugs was
between 35–45% over the decade. Multi-drug resistance (resis-
tance to 3 or more antibiotics) has remained constant at almost
one-third of isolates (range 25–37%, see Table 1).
Discussion
Pneumococcal infections place a high social, health and
economic burden on the infrastructure of resource-poor countries
such as Malawi [38]. The potential for the emergence of MDR S.
pneumoniae [39] threatens to further undermine these fragile
Figure 1. Trends in pneumococcal invasive disease and ART scale-up from 2002–2009 amongst adults and children. Data are derived
from blood and CSF cultures.
doi:10.1371/journal.pone.0017765.g001
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systems. Our hospital-based surveillance data shows that in the
context of the rapid scale-up of ART nationally, there has been a
concurrent decline in the number of invasive pneumococcal
infections detected and that importantly with the exception of
cotrimoxazole, the frequency of antibiotic resistant isolates,
including MDR strains, has remained relatively constant. In
particular, penicillin resistance amongst pneumococcal isolates was
15.1% in 2009 compared with 14.7% in 2000. This compares
favourably with some other African countries where resistance has
been reported in excess of 40% [31,32]. Long term surveillance is
a difficult undertaking but our data emphasise that it is vital to
maintain existing and create new sentinel surveillance sites
particularly in the era of vaccine introduction and with the
potential for serotype replacement and the emergence of resistant
strains [40].
HIV has a major impact on the frequency and mortality of
pneumococcal disease in SSA [41,42]. HIV-1 infection is linked to
higher rates of pneumococcal colonisation [9,31,43,44], is
associated with a different pattern of serotypes and higher rates
of antibiotic resistance [5,7,17,45,46]. Following the introduction
of ART in Malawi in 2004, we have observed an association
between ART scale-up and the decline in microbiologically
confirmed invasive pneumococcal disease over the 6 year period at
QECH (Pearson’s correlation r =20.91; p,0.001). These data
thus add to the increasing body of evidence that widespread
implementation of ART in national programmes will reduce the
burden of IPD [22,47].
Adults have a higher proportion of HIV co-infection among
patients with IPD compared to children. Any observation
regarding the effect of ART use would therefore be more likely
in adults where the impact of HIV is greatest and the scale-up of
ART has been most effective [21]. Indeed, at QECH we observed
a larger decline in IPD in adults than in children (Figure 3). To
further support the relationship between ART scale-up and a
decrease in IPD, we also compared trends in NTS blood culture
isolates in adults (Figure 4), a major HIV-associated pathogen in
Malawi and elsewhere in SSA [24]. We found that from 2005
through 2009 there was a consistent decrease in recovery of NTS
from adult blood cultures (Figure 3 and 4), suggesting that the
provision of free ART is impacting on IPD and HIV-related
bacteraemia rate in Malawi in general.
Alternate explanations for this decline in IPD admissions include
changes in the socio-demographic circumstances of the catchment
population over the time course of the study, such as improved
Figure 2. Pneumococcal recovery rates 2000–2009.
doi:10.1371/journal.pone.0017765.g002
Pneumococcal Surveillance in Malawi
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17765
access to healthcare, an effect that has been observed elsewhere
[48]. Specific research studies may also have had an impact on the
decline we observed. In 2004–2007, two large clinical studies
situated in the adult wards of QECH provided enhanced
pneumococcal surveillance through consistent efforts to improve
sample collection practices [17,35], particularly in blood culture
collection. The termination of these studies may have contributed to
the decline in IPD numbers by decreased ascertainment. However,
a decline in the isolation to sample number ratio particularly for
CSF samples supports the view that this is not simply an
Figure 3. Invasive pneumococcal infections from 2000–2009 separated into adult and pediatric disease. Data are derived from blood
and CSF cultures.
doi:10.1371/journal.pone.0017765.g003
Figure 4. Comparison between pneumococcal and non-typhoidal salmonellae (NTS) blood cultures amongst adults, 2000–2009.
doi:10.1371/journal.pone.0017765.g004
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ascertainment effect. Environmental conditions may have also
impacted on IPD rates through the progressive warming of colder
months. IPD is a well-described winter disease associated with the
colder months of the year in the Northern hemisphere [49,50,51].
In SSA, IPD is associated with the dry season, which also tends to
coincide with the colder months [52]. However, during ART scale-
up IPD remained seasonal, associated with the colder months and
there were no significant changes in average seasonal temperatures
over the decade to explain the decline in the frequency (Figure 5).
This data emphasises that surveillance needs to be conducted year-
round and that for planning purposes the greatest burden of disease
is in the cold dry months.
Figure 5. The relationship between seasonal rainfall and invasive pneumococcal disease among adults and children, by month,
2000–2009. Data are derived from blood and CSF cultures.
doi:10.1371/journal.pone.0017765.g005
Figure 6. Antibiotic resistance to individual drugs from 2000–2009.
doi:10.1371/journal.pone.0017765.g006
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The main benefit of cotrimoxazole prophylaxis in SSA is
believed to be the prevention of bacterial pneumonia, diarrhoea
and malaria infections [53,54]. This effect appears to be
maintained despite high prevalence of cotrimoxazole resistance
in clinical isolates [55,56,57]. In 2005, cotrimoxazole prophylaxis
for HIV-infected groups became national policy and a gradual
process of scale-up to all government hospitals was started.
However in QECH the availability of cotrimoxazole for
prophylactic use was irregular until 2007. Cotrimoxazole resis-
tance was already high and increased to almost universal levels
from 2002 (Figure 6), prior to its wide spread use as a prophylactic
agent. It is unclear if the increase in cotrimoxazole resistance was
linked to policy decisions, but our data would suggest that
cotrimoxazole prophylaxis scale-up has not driven resistance to the
other available antibiotics which is reassuring (Table 1). Indeed
our data does not support an immediate policy change regarding
cotrimoxazole prophylaxis but in the context of widespread
sulfadoxine/pyrimethamine malaria resistance does suggest that
further evaluation of its continued efficacy is required.
This survey also provides surveillance information on antibiotic
resistance trends in invasive pneumococcal isolates, which is
lacking from many areas across SSA. The frequency of
pneumococcal resistance to other commonly used antibiotics in
Blantyre has remained stable over the decade. In Malawi, 50% of
clinical pneumococcal isolates were previously reported as
tetracycline non-susceptible [24] and that has remained more or
less the same. Similarly, resistance rates for ceftriaxone, chloram-
phenicol, penicillin and erythromycin have remained largely
unchanged. The level of macrolide resistance has been increasing
worldwide [58,59] yet this has not been observed in QECH, where
erythromycin resistance remained very low at less than 2%. This
may be a consequence of restricted availability of macrolides
locally, in particular of the newer agents such as azithromycin and
clarithromycin. Ceftriaxone was introduced in 2004 as a first line
antibiotic and from 2004–2007 its use was tightly controlled. Since
2007 it has become more widely available for empirical treatment
of sepsis and meningitis. Although current pneumococcal isolates
are uniformly sensitive to ceftriaxone as determined by interna-
tionally accepted breakpoints [36], it is of concern that from 2009
we have begun to detect the first indications of an increase in
ceftriaxone MIC (from 0.0016 mg/ml to 0.125 mg/ml, unpub-
lished data). These subtle changes are the subject of further
surveillance and molecular analysis. Patterns of resistance in other
countries in the region may be different because of differing
patterns of antibiotic prescription and drug usage [60]. In Malawi,
antibiotics are only available through prescription and this policy
may have contributed to limiting the increase in pneumococcal
resistance rates (Figure 6). Only cotrimoxazole and tetracyclines
are widely available in the informal sector.
There are several potential limitations to this study, limitations
common to long term surveillance activity. Firstly the period of
surveillance stretches over ten years. During this time sampling
and processing guidelines have remained consistent but there has
been considerable turnover of clinicians and laboratory staff.
Secondly, we do not have data on HIV status, ART usage or
cotrimoxazole prophylaxis for all individual IPD admissions, and
therefore the impact of ART and cotrimoxazole prophylaxis can
only be inferred by temporal association. Thirdly, the observations
reported here are from until recently, the only long term
comprehensive surveillance site in Malawi and may not be
representative of the whole country. Fourthly, the microbiological
database is unable to define the potential impact of recurrent
admissions. We know that recurrent IPD disease in HIV-infected
individuals is common. However, we know that ART and
cotrimoxazole use will reduce the risk of recurrent disease [17].
We are not able to define the relative contribution of this to the
lower number of IPD cases. Finally, there has been a small but
steady rise in the socioeconomic status of the Malawian population
during the surveillance period [61]. Such change may in itself
contribute to pneumonia-related health outcomes [48]. Although
problematic in large urban populations, we are currently
undertaking community-based denominator surveys to further
strengthen our observation and provide a robust estimate of IPD
incidence in preparation for the imminent introduction of
conjugate pneumococcal vaccine into the expanded programme
of immunisation (EPI) in Malawi.
Conclusion
We have shown that the scale-up of free ART coincided with a
decrease in IPD. Whether ART scale up directly contributed to
the decrease in IPD is not certain but our data does demonstrate a
correlation between scale-up and decline in IPD. The introduction
of cotrimoxazole prophylaxis in HIV-infected groups has not
coincided with an increase in pneumococcal cotrimoxazole-
resistance which has been almost universal since 2002. Antibiotic
resistance rates in general have remained stable over the past
decade. This data emphasises the well documented need for
improved infectious disease surveillance across the region, but
more specifically it will be vital for monitoring the effects of the
introduction of pneumococcal conjugate vaccine as it is introduced
into national immunisation programmes across SSA, and the
monitoring of strategies to limit antimicrobial resistance to this
important pathogen.
Table 1. Relationship between cotrimoxazole resistance and resistance to other commonly used antibiotics in Malawi:
erythromycin, chloramphenicol, penicillin, tetracycline or cetriaxone.
Resistance Combinations Resistance rates (%)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Cotrimoxazole (CTM) 73.8 74.9 92.8 92.0 90.3 94.2 91.6 95.0 91.0 92.6
CTM + 1 other antibiotic 27.4 30.1 31.2 33.2 33.1 33.7 27.8 25.8 25.3 27.7
CTM + 2 other antibiotics 29.4 25.4 33.4 37.4 34.7 30.0 37.2 31.3 32.0 28.4
CTM + 3 other antibiotics 0.9 1.2 0.8 0.9 0.6 0.5 1.7 1.0 0.9 0.0
CTM + 4 other antibiotics 0.0 0.0 0.0 0.0 0.0 0.0 0.37 0.0 0.0 0.0
doi:10.1371/journal.pone.0017765.t001
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